BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17920283)

  • 21. Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington's disease.
    Ragauskas S; Leinonen H; Puranen J; Rönkkö S; Nymark S; Gurevicius K; Lipponen A; Kontkanen O; Puoliväli J; Tanila H; Kalesnykas G
    PLoS One; 2014; 9(12):e113317. PubMed ID: 25469887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The absence of the aryl hydrocarbon receptor in the R6/1 transgenic mouse model of Huntington's disease improves the neurological phenotype.
    Angeles-López QD; García-Lara L; Aguirre-Pineda N; Castañeda-Arellano R; Elizondo-Azuela G; Pérez-Severiano F; Segovia J
    Behav Brain Res; 2021 Jun; 408():113230. PubMed ID: 33684424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease.
    El-Akabawy G; Rattray I; Johansson SM; Gale R; Bates G; Modo M
    BMC Neurosci; 2012 Aug; 13():97. PubMed ID: 22876937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
    Johnson MA; Rajan V; Miller CE; Wightman RM
    J Neurochem; 2006 May; 97(3):737-46. PubMed ID: 16573654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.
    Smith R; Petersén A; Bates GP; Brundin P; Li JY
    Neurobiol Dis; 2005 Dec; 20(3):673-84. PubMed ID: 15967669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.
    Ribchester RR; Thomson D; Wood NI; Hinks T; Gillingwater TH; Wishart TM; Court FA; Morton AJ
    Eur J Neurosci; 2004 Dec; 20(11):3092-114. PubMed ID: 15579164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
    Smith KM; Matson S; Matson WR; Cormier K; Del Signore SJ; Hagerty SW; Stack EC; Ryu H; Ferrante RJ
    Biochim Biophys Acta; 2006 Jun; 1762(6):616-26. PubMed ID: 16647250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progressive CAG expansion in the brain of a novel R6/1-89Q mouse model of Huntington's disease with delayed phenotypic onset.
    Vatsavayai SC; Dallérac GM; Milnerwood AJ; Cummings DM; Rezaie P; Murphy KP; Hirst MC
    Brain Res Bull; 2007 Apr; 72(2-3):98-102. PubMed ID: 17352932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice.
    Bolivar VJ; Manley K; Messer A
    Brain Res; 2004 Apr; 1005(1-2):29-35. PubMed ID: 15044061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.
    Rising AC; Xu J; Carlson A; Napoli VV; Denovan-Wright EM; Mandel RJ
    Exp Neurol; 2011 Apr; 228(2):173-82. PubMed ID: 21192926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
    Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
    Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice.
    Dickson E; Soylu-Kucharz R; Petersén Å; Björkqvist M
    Mol Metab; 2022 Mar; 57():101439. PubMed ID: 35007790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
    Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
    J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
    Popovic N; Maingay M; Kirik D; Brundin P
    Exp Neurol; 2005 May; 193(1):65-74. PubMed ID: 15817265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced expression of PSA-NCAM in the hippocampus and piriform cortex of the R6/1 and R6/2 mouse models of Huntington's disease.
    van der Borght K; Brundin P
    Exp Neurol; 2007 Mar; 204(1):473-8. PubMed ID: 17187781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease.
    Wood NI; Glynn D; Morton AJ
    Neurobiol Dis; 2011 Jun; 42(3):427-37. PubMed ID: 21324361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
    García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
    J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.
    Stack EC; Kubilus JK; Smith K; Cormier K; Del Signore SJ; Guelin E; Ryu H; Hersch SM; Ferrante RJ
    J Comp Neurol; 2005 Oct; 490(4):354-70. PubMed ID: 16127709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease.
    Wood NI; Carta V; Milde S; Skillings EA; McAllister CJ; Ang YL; Duguid A; Wijesuriya N; Afzal SM; Fernandes JX; Leong TW; Morton AJ
    PLoS One; 2010 Feb; 5(2):e9077. PubMed ID: 20174443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease.
    Sjögren M; Soylu-Kucharz R; Dandunna U; Stan TL; Cavalera M; Sandelius Å; Zetterberg H; Björkqvist M
    Neurobiol Dis; 2019 Dec; 132():104560. PubMed ID: 31419548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.